A specific monoclonal antibody targeting C-36 peptide of alpha1-antitrypsin as a tool in respiratory research Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021
The type II and clara cell specific monoclonal antibody (MMC4) recognises aminopeptidase N Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004
B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020
Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Monitoring of monoclonal antibody therapy with a new recovery ELISA assay technique (R-ELISA®) Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Differences in the response to treatment with monoclonal antibodies according to age Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Omalizumab, an anti-immunoglobin E antibody, is not associated with an increased risk of immunological reactions Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
High prevalence of serum IgA antibodies against gliadin in patients with interstitial lung diseases confirmed by immunoblotting Source: Eur Respir J 2003; 22: Suppl. 45, 227s Year: 2003
Screening mimic peptide of lipopolysaccharide binding protein binding to CD14 Source: Annual Congress 2007 - Lung injury and repair: from in vitro to in vivo Year: 2007
Detection of serum anti-endothelial cell antibodies (AECA) in COPD rats Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide Source: Eur Respir J 2012; 40: 152-160 Year: 2012
Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
Detection of antineutrophil cytoplasmic antibodies (ANCA) and antinuclear antibodies (ANA) in children and adults with cystic fibrosis (CF) Source: Eur Respir J 2007; 30: Suppl. 51, 648s Year: 2007